Department of Pathology, College of Veterinary Medicine, The University of Georgia, Athens, GA, USA.
Department of Pathology, College of Veterinary Medicine, and Department of Basic Sciences, AU/UGA Medical Partnership, The University of Georgia, Athens, GA, USA.
Adv Exp Med Biol. 2021;1348:139-159. doi: 10.1007/978-3-030-80614-9_6.
Repair and healing of injured and diseased tendons has been traditionally fraught with apprehension and difficulties, and often led to rather unsatisfactory results. The burgeoning research field of growth factors has opened new venues for treatment of tendon disorders and injuries, and possibly for treatment of disorders of the aorta and major arteries as well. Several chapters in this volume elucidate the role of transforming growth factor β (TGFß) in pathogenesis of several heritable disorders affecting soft tissues, such as aorta, cardiac valves, and tendons and ligaments. Several members of the bone morphogenetic group either have been approved by the FDA for treatment of non-healing fractures or have been undergoing intensive clinical and experimental testing for use of healing bone fractures and tendon injuries. Because fibroblast growth factors (FGFs) are involved in embryonic development of tendons and muscles among other tissues and organs, the hope is that applied research on FGF biological effects will lead to the development of some new treatment strategies providing that we can control angiogenicity of these growth factors. The problem, or rather question, regarding practical use of imsulin-like growth factor I (IGF-I) in tendon repair is whether IGF-I acts independently or under the guidance of growth hormone. FGF2 or platelet-derived growth factor (PDGF) alone or in combination with IGF-I stimulates regeneration of periodontal ligament: a matter of importance in Marfan patients with periodontitis. In contrast, vascular endothelial growth factor (VEGF) appears to have rather deleterious effects on experimental tendon healing, perhaps because of its angiogenic activity and stimulation of matrix metalloproteinases-proteases whose increased expression has been documented in a variety of ruptured tendons. Other modalities, such as local administration of platelet-rich plasma (PRP) and/or of mesenchymal stem cells have been explored extensively in tendon healing. Though treatment with PRP and mesenchymal stem cells has met with some success in horses (who experience a lot of tendon injuries and other tendon problems), the use of PRP and mesenchymal stem cells in people has been more problematic and requires more studies before PRP and mesenchymal stem cells can become reliable tools in management of soft tissue injuries and disorders.
传统上,修复和治疗受伤和患病的肌腱一直充满了担忧和困难,而且往往导致结果不太令人满意。生长因子这一新兴研究领域为治疗肌腱疾病和损伤开辟了新途径,也可能为治疗主动脉和主要动脉疾病开辟了新途径。本卷的几个章节阐明了转化生长因子β(TGFβ)在几种影响软组织的遗传性疾病(如主动脉、心脏瓣膜以及肌腱和韧带)发病机制中的作用。骨形态发生蛋白组的几个成员已经获得 FDA 批准用于治疗不愈合的骨折,或者正在进行密集的临床和实验测试,以用于治疗骨折和肌腱损伤。由于成纤维细胞生长因子(FGFs)参与肌腱和肌肉等组织和器官的胚胎发育,因此希望对 FGF 生物学效应的应用研究将导致开发一些新的治疗策略,前提是我们能够控制这些生长因子的血管生成。在肌腱修复中实际应用胰岛素样生长因子 I(IGF-I)的问题,或者更确切地说是疑问,是 IGF-I 是独立作用还是在生长激素的指导下作用。FGF2 或血小板衍生生长因子(PDGF)单独或与 IGF-I 联合刺激牙周韧带再生:这对于患有牙周炎的马凡综合征患者非常重要。相比之下,血管内皮生长因子(VEGF)似乎对实验性肌腱愈合有相当有害的影响,可能是因为其血管生成活性和基质金属蛋白酶的刺激-其在各种破裂的肌腱中已被证明表达增加。其他方式,如富含血小板的血浆(PRP)和/或间充质干细胞的局部给药,在肌腱愈合中已经得到了广泛的探索。尽管 PRP 和间充质干细胞的治疗在马(经常遭受很多肌腱损伤和其他肌腱问题)中取得了一些成功,但在人类中使用 PRP 和间充质干细胞更成问题,并且需要更多的研究,然后 PRP 和间充质干细胞才能成为软组织损伤和疾病管理的可靠工具。